ArticleCureus2026
Metaplastic Breast Carcinoma: Clinicopathological Characteristics, Treatment Patterns, and Outcomes.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetaplastic breast carcinoma (MBC) is a rare and aggressive subtype of breast cancer, accounting for less than 1% of all cases. MBC is characterized by a metaplastic transformation of glandular epithelium into squamous and/or mesenchymal elements. Most tumors are triple-negative, lacking expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), which limits targeted therapeutic options. MBC also exhibits marked histopathological heterogeneity and high chemoresistance.
methodsWe conducted a retrospective study of 15 patients with histopathologically confirmed MBC treated at a tertiary care center in India. All cases demonstrated a triple-negative immunophenotype (ER < 1%, PR < 1%, HER2-negative), with documented metaplastic differentiation. Detailed data on demographics, clinicopathological features, treatment, and outcomes were collected and analyzed.
resultsThe median age at diagnosis was 52 years. All patients presented with advanced disease: stage II in 60% (n = 9) and stage III in 40% (n = 6). Metaplastic differentiation included spindle cell features in 40% (n = 6), squamous features in 33.3% (n = 5), and mixed patterns in 26.7% (n = 4). Tumors were more commonly located in the right breast (73.3%, n = 11). Surgical management included mastectomy in 60% (n = 9) and breast-conserving surgery in 26.7% (n = 4). Neoadjuvant chemotherapy (NAC) was administered to six patients (40%), achieving a pathological complete response (pCR) in two of these (33.3%). Adjuvant chemotherapy was given to seven patients (46.7%), and 11 patients (73.3%) received radiotherapy. At the last follow-up, six (40%) were alive and disease-free, two (13.3%) were alive with disease, three (20%) had died, two (13.3%) were lost to follow-up, and two (13.3%) had incomplete assessment.
conclusionsMBC in this cohort presented with aggressive histopathological features and predominantly advanced-stage disease. These findings highlight the need for improved breast cancer awareness, early detection, and individualized treatment strategies, particularly in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.